Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo
McKinsey
Express Scripts
AstraZeneca
Merck
Baxter
Chinese Patent Office
Queensland Health

Generated: May 23, 2018

DrugPatentWatch Database Preview

Dasatinib - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for dasatinib and what is the scope of dasatinib freedom to operate?

Dasatinib
is the generic ingredient in two branded drugs marketed by Apotex Inc and Bristol Myers Squibb, and is included in two NDAs. There are five patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Dasatinib has one hundred and nineteen patent family members in thirty-nine countries.

There are fourteen drug master file entries for dasatinib. Two suppliers are listed for this compound.
Pharmacology for dasatinib
Medical Subject Heading (MeSH) Categories for dasatinib
Synonyms for dasatinib
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
2-{6-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide
2359AH
302962-49-8
302962-49-8 pound not863127-77-9
49310-EP2270008A1
49310-EP2292617A1
49310-EP2311840A1
5-Thiazolecarboxamide, monohydrate
5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-
5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-
A-2429
AB0066750
AB01273956_03
AB01273956-01
AB01273956-02
AC-22749
AC1MI3ET
AC1Q2P0C
AK-47532
AKOS015902363
AM20080877
AmbotzLS-1203
AN-5289
anh. dasatinib
anhydrous dasatinib
ANW-43935
AOB87355
API0002220
AX8035158
BCB03_000715
BCP9000589
BCPP000263
BDBM13216
BMS 345825
BMS 354825
BMS 354825|||Sprycel
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825-03
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS-354825;BMS354825;BMS 354825
BMS354825
BR-47532
BRD-K49328571-001-07-7
CAS-302962-49-8
CD0138
CHEBI:49375
CHEMBL1421
cid_3062316
CS-0100
CTK8B4120
D-3307
D03658
D0E6XR
Dasatinib - BMS-354825
dasatinib (anh.)
Dasatinib (anhydrous)
Dasatinib (BMS-354825)
Dasatinib (INN)
Dasatinib (USAN)
Dasatinib [USAN:INN]
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib BMS-354825
Dasatinib, BMS 354825
Dasatinib,BMS-354825
Dasatinib;
dasatinibum
DB01254
DR003007
DSSTox_CID_20979
DSSTox_GSID_40979
DSSTox_RID_79608
DTXSID4040979
EN002710
EX-A401
FC0026
FT-0084503
FT-0650671
GS-6548
GTPL5678
HE333223
HMS2043N05
HMS3244A05
HMS3244A06
HMS3244B05
HMS3265C19
HMS3265C20
HMS3265D19
HMS3265D20
HMS3654K05
HY-10181
I14-1972
KB-274688
KB-76415
Kinome_3650
KS-0000027F
LS-186641
LS-187028
LS-187773
MFCD11046566
MLS003915609
MLS004774145
MLS006010904
MolPort-003-846-143
N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide
n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thia
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NCGC00181129-02
NCGC00181129-03
NCGC00181129-05
NCGC00181129-06
NSC-732517
NSC-759877
NSC732517
NSC759877
Pharmakon1600-01502275
Q-101345
QCR-106
RTR-013021
RTR-021205
s1021
SC-22079
SCHEMBL8226
SMR002529551
Sprycel
Sprycel (Bristol Meyers)
SPRYCEL (TN)
Spyrcel
SR-00000000554
SR-00000000554-5
ST2419212
SYN1036
Tox21_112736
Tox21_112736_1
TR-013021
TRA0075817
UNII-X78UG0A0RN
X78UG0A0RN
Z2786158251
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
ZINC3986735

US Patents and Regulatory Information for dasatinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-006 Oct 28, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for dasatinib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,189,854 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
6,979,694 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
9,382,219 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
8,993,567 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for dasatinib

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1169038/01 Switzerland ➤ Try a Free Trial FORMER OWNER: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH
2013000012 Germany ➤ Try a Free Trial PRODUCT NAME: DASATINIB UND PHARMAZEUTISCH GEEIGNETE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-009 EU/1/06/363/010-011 EU/1/06/363/012-015 20061120
00567 Netherlands ➤ Try a Free Trial PRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 .... 009 20061120
13/003 Ireland ➤ Try a Free Trial PRODUCT NAME: DASATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Baxter
AstraZeneca
US Department of Justice
Citi
Harvard Business School
Cantor Fitzgerald
Cipla
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.